Unraveling the Impact of miR-146a in Pulmonary Arterial Hypertension Pathophysiology and Right Ventricular Function DOI Open Access
Joana Gomes, Pedro Mendes‐Ferreira, Rui Adão

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(15), P. 8054 - 8054

Published: July 24, 2024

Pulmonary arterial hypertension (PAH) is a chronic disorder characterized by excessive pulmonary vascular remodeling, leading to elevated resistance and right ventricle (RV) overload failure. MicroRNA-146a (miR-146a) promotes smooth muscle cell proliferation neointimal hyperplasia, both hallmarks of PAH. This study aimed investigate the effects miR-146a through pharmacological or genetic inhibition on experimental PAH RV pressure animal models. Additionally, we examined overexpression human artery cells (hPASMCs). Here, showed that genic expression was increased in lungs patients with plasma monocrotaline (MCT) rats. Interestingly, ablation improved hypertrophy systolic pressures Sugen 5415/hypoxia (SuHx) banding (PAB) mice. Pharmacological remodeling PAB-wild type mice MCT rats, enhanced exercise capacity However, did not affect proliferation, migration, apoptosis control-hPASMCs. Our findings show may play significant role function representing promising therapeutic target for and, consequently,

Language: Английский

Exploring ncRNA-mediated regulation of EGFR signalling in glioblastoma: From mechanisms to therapeutics DOI
Riya Thapa, Muhammad Afzal, Ahsas Goyal

et al.

Life Sciences, Journal Year: 2024, Volume and Issue: 345, P. 122613 - 122613

Published: April 4, 2024

Language: Английский

Citations

26
A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer DOI Creative Commons
Katia Grillone, Giulio Caridà, Francesco Luciano

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Aug. 5, 2024

Targeting non-coding RNAs (ncRNAs), including microRNAs (miRNAs) and long (lncRNAs), has recently emerged as a promising strategy for treating malignancies other diseases. In recent years, the development of ncRNA-based therapeutics targeting protein-coding genes also gained momentum. This review systematically examines ongoing completed clinical trials to provide comprehensive overview emerging landscape therapeutics. Significant efforts have been made advance ncRNA early studies. The most advanced conducted with small interfering (siRNAs), miRNA replacement using nanovector-entrapped mimics, or silencing by antisense oligonucleotides. While siRNA-based already received FDA approval, inhibitors, lncRNA-based are still under evaluation in preclinical We critically discuss rationale methodologies strategies illustrate this rapidly evolving field.

Language: Английский

Citations

24
MicroRNA-21's role in PTEN suppression and PI3K/AKT activation: Implications for cancer biology DOI
Himmat Singh Chawra, Mohit Agarwal, Anurag Mishra

et al.

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 254, P. 155091 - 155091

Published: Jan. 3, 2024

Language: Английский

Citations

21
lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways DOI
Raed Obaid Saleh, Mushtak T.S. Al-Ouqaili,

Eyhab Ali

et al.

Medical Oncology, Journal Year: 2024, Volume and Issue: 41(2)

Published: Jan. 9, 2024

Language: Английский

Citations

19
MircoRNAs predict and modulate responses to chemotherapy in leukemic patients DOI
Doha El‐Sayed Ellakwa,

Mohamed Ahmed Abdelmalek,

Mostafa Mostafa

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 14, 2025

Language: Английский

Citations

6
Innovations in RNA therapeutics: a review of recent advances and emerging technologies DOI
Tuward J. Dweh,

Glay Jr Eric Wulu,

John Kessellie Jallah

et al.

Nucleosides Nucleotides & Nucleic Acids, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 25

Published: Jan. 13, 2025

The field of biomedical science has witnessed another milestone with the advent RNA-based therapeutics. This review explores three major RNA molecules, namely: messenger (mRNA), interference technology (RNAi), and Antisense Oligonucleotide (ASO), analyses U.S. Food Drug Administration drugs from 14 pharmaceutical companies in terms targeted genes, diseases types, clinical trials status, mode delivery, year production. Many such are clinically approved or pending approval by (FDA) alongside other leading agencies. Regarding diseases, this article emphasizes cancer therapy, genetic viral infections, two categories drug delivery systems include vectors nanoparticles. Despite tremendous progress made, key issues associated these stability, off-target activities payloads, efficiency cellular uptake, innovative need for engineering techniques modifications. transformative potential therapeutics role technologies addressing needs, paving way a new era precision medicine.

Language: Английский

Citations

2
Non-coding RNAs: emerging biomarkers and therapeutic targets in cancer and inflammatory diseases DOI Creative Commons
Basma Hossam Abdelmonem,

Lereen T. Kamal,

Lilian Waheed Wardy

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: March 10, 2025

Non-coding RNAs (ncRNAs) have a significant role in gene regulation, especially cancer and inflammatory diseases. ncRNAs, such as microRNA, long non-coding RNAs, circular alter the transcriptional, post-transcriptional, epigenetic expression levels. These molecules act biomarkers possible therapeutic targets because aberrant ncRNA has been directly connected to tumor progression, metastasis, response therapy research. ncRNAs’ interactions with multiple cellular pathways, including MAPK, Wnt, PI3K/AKT/mTOR, impact processes like proliferation, apoptosis, immune responses. The potential of RNA-based therapeutics, anti-microRNA microRNA mimics, restore normal is being actively studied. Additionally, tissue-specific patterns ncRNAs offer unique opportunities for targeted therapy. Specificity, stability, responses are obstacles use ncRNAs; however, novel strategies, modified oligonucleotides delivery systems, developed. profiling may result more individualized successful treatments precision medicine advances, improving patient outcomes creating early diagnosis monitoring opportunities. current review aims investigate roles diseases, focusing on their mechanisms regulation implications non-invasive diagnostics therapies. A comprehensive literature was conducted using PubMed Google Scholar, research published between 2014 2025. Studies were selected based rigorous inclusion criteria, peer-reviewed status relevance Non-English, non-peer-reviewed, inconclusive studies excluded. This approach ensures that findings presented high-quality relevant sources.

Language: Английский

Citations

1
The Regulatory Role of MicroRNAs in Obesity and Obesity-Derived Ailments DOI Open Access
Javier A. Benavides‐Aguilar, Andrea Torres‐Copado,

José Isidoro-Sánchez

et al.

Genes, Journal Year: 2023, Volume and Issue: 14(11), P. 2070 - 2070

Published: Nov. 13, 2023

Obesity is a condition that characterized by the presence of excessive adipose tissue in body. has become one main health concerns worldwide since it can lead to other chronic ailments, such as type 2 diabetes or fatty liver disease, and could be an aggravating factor infections. MicroRNAs (miRNAs) are small, non-coding RNA molecules regulate gene expression play important role controlling crucial biological processes involved onset obesity, lipogenesis, adipogenesis, lipid metabolism, regulation cytokines chemokines. Moreover, chemical compounds present food packaging alter miRNA aforementioned mechanisms related progression. Furthermore, therapies, bariatric surgery aerobic exercise training, also influence profile miRNAs obesity. Therefore, review provides insight into current research on obesity obesity-derived intending develop novel therapies effectively manage these disorders.

Language: Английский

Citations

18
LncRNA-miRNA interaction is involved in colorectal cancer pathogenesis by modulating diverse signaling pathways DOI
Shadia Hamoud Alshahrani,

Zeina S. M. Al-Hadeithi,

Sami G. Almalki

et al.

Pathology - Research and Practice, Journal Year: 2023, Volume and Issue: 251, P. 154898 - 154898

Published: Oct. 16, 2023

Language: Английский

Citations

17
Exploring the Therapeutic Significance of microRNAs and lncRNAs in Kidney Diseases DOI Open Access
Luis Alberto Bravo-Vázquez, Sujay Paul,

Miriam Guadalupe Colín-Jurado

et al.

Genes, Journal Year: 2024, Volume and Issue: 15(1), P. 123 - 123

Published: Jan. 19, 2024

MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) are two crucial classes of transcripts that belong to the major group (ncRNAs). These RNA molecules have significant influence over diverse molecular processes due their role as regulators gene expression. However, dysregulated expression these ncRNAs constitutes a fundamental factor in etiology progression wide variety multifaceted human diseases, including kidney diseases. In this context, past years, compelling evidence has shown miRNAs lncRNAs could be prospective targets for development next-generation drugs against diseases they participate number disease-associated processes, such podocyte nephron death, renal fibrosis, inflammation, transition from acute injury chronic disease, vascular changes, sepsis, pyroptosis, apoptosis. Hence, current review, we critically analyze recent findings concerning therapeutic inferences pathophysiological context Additionally, with aim driving advances formulation ncRNA-based tailored management discuss some key challenges future prospects should addressed forthcoming investigations.

Language: Английский

Citations

8